• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

万变不离其宗：ALK 阳性非小细胞肺癌中克唑替尼反应的生物标志物？

Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?

机构信息

Massachusetts General Hospital Cancer Center; and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA.

出版信息

Clin Cancer Res. 2012 Sep 1;18(17):4479-81. doi: 10.1158/1078-0432.CCR-12-1952. Epub 2012 Aug 21.

DOI:10.1158/1078-0432.CCR-12-1952
PMID:22912388
Abstract

Anaplastic lymphoma kinase (ALK) gene rearrangements are found in approximately 5% of non-small cell lung carcinoma patients and confer sensitivity to ALK inhibitors such as crizotinib. The particular ALK fusion expressed may have an impact on protein stability and sensitivity to crizotinib, and this may underlie the heterogeneity in responses observed in the clinic.

摘要

间变性淋巴瘤激酶 (ALK) 基因重排约见于 5%的非小细胞肺癌患者，对 ALK 抑制剂（如克唑替尼）敏感。表达的特定 ALK 融合可能对蛋白稳定性和对克唑替尼的敏感性有影响，这可能是临床观察到的反应异质性的基础。

相似文献

1
Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?万变不离其宗：ALK 阳性非小细胞肺癌中克唑替尼反应的生物标志物？
Clin Cancer Res. 2012 Sep 1;18(17):4479-81. doi: 10.1158/1078-0432.CCR-12-1952. Epub 2012 Aug 21.
2
Targeting anaplastic lymphoma kinase in lung cancer.针对肺癌中的间变性淋巴瘤激酶。
Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2.
3
Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.克唑替尼：ALK 阳性非小细胞肺癌的新治疗选择。
Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5.
4
EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.EML4-ALK 融合通过 RT-PCR 检测与 FISH 检测在晚期非小细胞肺癌患者中对克唑替尼的反应相似。
J Thorac Oncol. 2015 Nov;10(11):1546-52. doi: 10.1097/JTO.0000000000000668.
5
Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.将ALK检测和克唑替尼纳入非小细胞肺癌患者常规治疗的经验。
Onkologie. 2013;36(6):342-7. doi: 10.1159/000351163. Epub 2013 Apr 30.
6
ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.ALK 抑制剂克唑替尼联合鞘内注射甲氨蝶呤治疗非小细胞肺癌伴脑膜转移。
Lung Cancer. 2012 May;76(2):253-4. doi: 10.1016/j.lungcan.2012.02.003. Epub 2012 Mar 3.
7
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.EML4-ALK 融合变体的差异蛋白稳定性和 ALK 抑制剂敏感性。
Clin Cancer Res. 2012 Sep 1;18(17):4682-90. doi: 10.1158/1078-0432.CCR-11-3260. Epub 2012 Aug 21.
8
Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.三例棘皮动物微管相关蛋白样 4-间变性淋巴瘤激酶融合型癌基因阳性非小细胞肺癌患者对克唑替尼的良好反应。
Cancer Sci. 2011 Aug;102(8):1602-4. doi: 10.1111/j.1349-7006.2011.01970.x.
9
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.在对阿来替尼耐药的两个存在 ALK 重排的非小细胞肺癌（NSCLC）患者中发现了一种新型的 HIP1-ALK 融合变体和 ALK I1171（I1171N/S）突变。
J Thorac Oncol. 2014 Dec;9(12):1821-5. doi: 10.1097/JTO.0000000000000368.
10
Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.间变性淋巴瘤激酶重排非小细胞肺癌的靶向治疗现状。
Clin Pharmacol Ther. 2014 Jan;95(1):15-23. doi: 10.1038/clpt.2013.200. Epub 2013 Oct 3.

引用本文的文献

1
Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis.通过蛋白质组范围的信号网络分析阐明肺腺癌中的协同依赖关系。
PLoS One. 2019 Jan 7;14(1):e0208646. doi: 10.1371/journal.pone.0208646. eCollection 2019.
2
Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non-Small Cell Lung Cancer.非小细胞肺癌中基因融合和外显子跳跃事件产生的嵌合RNA靶向新一代测序检测系统的设计、优化及多中心评估
J Mol Diagn. 2019 Mar;21(2):352-365. doi: 10.1016/j.jmoldx.2018.10.003. Epub 2018 Dec 4.
3
Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology.
采用 NanoString 技术检测 FFPE 肺癌样本中的 ALK 融合转录本。
BMC Pulm Med. 2017 May 26;17(1):86. doi: 10.1186/s12890-017-0428-0.
4
Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.晚期非小细胞肺癌中的生物标志物与靶向全身治疗
Mol Aspects Med. 2015 Nov;45:55-66. doi: 10.1016/j.mam.2015.06.009. Epub 2015 Jul 14.
5
The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌分子检测的外部质量评估的相关性：两轮试点结果显示仍有优化空间。
PLoS One. 2014 Nov 11;9(11):e112159. doi: 10.1371/journal.pone.0112159. eCollection 2014.
6
Anchored multiplex PCR for targeted next-generation sequencing.靶向下一代测序的锚定多重 PCR。
Nat Med. 2014 Dec;20(12):1479-84. doi: 10.1038/nm.3729. Epub 2014 Nov 10.